Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Approved
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
1 competitor in ALS (SOD1)
View Full LandscapeTarget Indication
ALS (SOD1)
Mechanism of Action
Antisense Oligonucleotide
Clinical Trial
NCT02623699Last updated: 12/3/2025
Qalsody
Qalsody is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.